ARCHIVES

ImClone Offered C225 Deal To Seven Firms Prior To BMS

This article is from The Cancer Letter archive.

Vol. 28 No. | March 8, 2002

Download PDF Visit The Full Archive

Related Articles

Enzalutamide Reduced Risk of Progression By 81 Percent in Metastatic Prostate Cancer

June 27, 2014

ASPO Honors Gritz.

May 25, 2001

Copeland Named Director, UF Cancer Center

February 10, 1995

Rich Left AMC “For Personal Reasons”

April 21, 1989

Program Announcements For Tobacco Research

January 21, 1983

Funding opportunities: ASCO breast cancer research award; Lustgarten Foundation prostate cancer research award; NCI program announcements available.

March 5, 2004